Radioprotective effects of on 01210.na upon oral administration

Journal of Radiation Research

Volumn 53, Issue 3, 2012, Pages 368-376

  Suman, Shubhankar ^a   Datta, Kamal ^a   Doiron, Kathryn ^a   Ren, Chen ^b   Kumar, Ramesh ^b   Taft, David R ^c   Fornace, Albert J ^a,d   Maniar, Manoj ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b Onconova Therapeutics Inc   (United States)

^c LONG ISLAND UNIVERSITY   (United States)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Ex RAD; Hematopoietic protection; ON 01210.Na; Oral; Prophylactic; Radiopro tectant; Radioprotection

Indexed keywords

BIOCHEMISTRY; DRUG DELIVERY; MAMMALS; SODIUM;

EX-RAD; HEMATOPOIETIC PROTECTION; NA; ON 01210.; ORAL; ORAL ADMINISTRATION; ORAL ROUTE; PROPHYLACTIC; RADIOPRO-TECTANT; RADIOPROTECTION;

PHARMACOKINETICS;

MUS;

EID: 84863461654     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1269/jrr.11191     Document Type: Article

References (28)

1. Mettler FAJ and Voelz GL (2002) Major radiation exposure-what to expect and how to respond. N Engl J Med 346: 1554-1561.
2. Ring JP (2004) Radiation risks and dirty bombs. Health Physics 86: S42-S47.
3. Weiss JF and Landauer MR (2009) History and development of radiation-protective agents. Int J Radiat Biol 85: 539-573.
4. Pellmar TC and Rockwell S (2005) Priority list of research areas for radiological nuclear threat countermeasures. Radiat Res 163: 115-123.
5. Coleman CN and Parker GW (2009) Radiation terrorism: what society needs from the radiobiology-radiation protection and radiation oncology communities. J Radiol Prot 29: A159-A169.
6. Moulder JE and Cohen EP (2007) Future strategies for mitigation and treatment of chronic radiation-induced normal tissue injury. Semin Radiat Oncol 17: 141-148.
7. Gourmelon P, et al (2005) Involvement of the central nervous system in radiation-induced multi-organ dysfunction and/or failure. BJR Suppl 27: 62-68.
8. Zenk JL (2007) New therapy for the prevention and prophylactic treatment of acute radiation syndrome. Expert Opin Investig Drugs 16: 767-770.
9. Stone HB, et al (2004) Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop. Radiat Res 162: 711-728.
10. Bonner HS and Shaw LM (2002) New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. J Clin Pharmacol 42: 166-174.
11. Burdelya LG, et al (2008) An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320: 226-230.
12. Pamujula S, et al (2005) Radioprotection in mice following oral delivery of amifostine nanoparticles. Int J Radiat Biol 81: 251-257.
13. Whitnall MH, et al (2002) Radioprotective efficacy and acute toxicity of 5-androstenediol after subcutaneous or oral administration in mice. Immunopharmacol Immunotoxicol 24: 595-626.
14. Landauer MR, Srinivasan V and Seed TM (2003) Genistein treatment protects mice from ionizing radiation injury. J Appl Toxicol 23: 379-385.
15. Yildiz M, Sahin B and Sahin A (2006) Acute effects of oral melatonin administration on arterial distensibility, as determined by carotid-femoral pulse wave velocity, in healthy young men. Exp Clin Cardiol 11: 311-313.
16. Ghosh SP, et al (2009). Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms. Radiat Res 171: 173-179.
17. Chun AW, et al (2011) Effects of formulation and route of administration on the systemic availability of Ex-RAD, a new radioprotectant, in preclinical species. Biopharm Drug Dispos 32: 99-111.
18. Chun AW, et al (2009) Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. Cancer Chemother Pharmacol 65: 177-186.
19. Ghosh SP, et al (2009) Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector. Int J Radiat Biol 85: 598-606.
20. Singh VK, Brown DS and Kao TC (2010) Alpha-tocopherol succinate protects mice from gamma-radiation by induction of granulocyte-colony stimulating factor. Int J Radiat Biol 86: 12-21.
21. Kodell RL, et al (2010) Determination of sample sizes for demonstrating efficacy of radiation countermeasures. Biometrics 66: 239-248.
22. Brook I, et al (2002) Management of postirradiation sepsis. Mil Med 167: 105-106.
23. Brook I, et al (2004) Management of postirradiation infection: lessons learned from animal models. Mil Med 169: 194-197.
24. Patt HM, et al (1949) Cysteine Protection against X Irradiation. Science 110: 213-214.
25. Hosseinimehr SJ (2007) Trends in the development of radioprotective agents. Drug Discov Today 12: 794-805.
26. Shaeffer J, et al (1986) Radioprotective effect of polyethylene glycol. Radiat Res 107: 125-135.
27. Bryant B, Knights K and Salerno E (2010) Pharmacology for Health Professionals. 3rd edition, Elsevier Australia.
28. Greenberger JS (2009) Radioprotection. In Vivo 23: 323-336.